Dxd is a pharmaceutical intermediate used in the synthesis of antibody-drug conjugates. It is a derivative of exatecan, a topoisomerase I inhibitor, and serves as the cytotoxic payload in targeted cancer therapies.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Dxd?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Exatecan mesylate
pharmaceutical raw material
Exatecan
pharmaceutical raw material
Exatecan hydrochloride
pharmaceutical raw material
(3R)-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid
pharmaceutical intermediate
MC-GGFG-Exatecan
pharmaceutical intermediate
7-Chloro-1,2,3,4-tetrahydrobenzo[b]azepin-5-one
pharmaceutical intermediate
2,6-dichloro-3-nitropyridine
pharmaceutical intermediate
N-[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]-2-hydroxyacetamide
PLXLYXLUCNZSAA-QLXKLKPCSA-N
CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C5[C@H](CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)NC(=O)CO)O
Sourcing Dxd?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.